The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: hype or hope?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

1. Gut Microbiome and Bile Acid Interactions: Mechanistic Implications for Cholangiocarcinoma Development, Immune Resistance, and Therapy.The American journal of pathology · 2025
   Review
2. Relevance of Bile Acids in Cholangiocarcinoma Pathogenesis: Critical Revision and Future Directions.Cells · 2023
   Review
3. Interactive role of diabetes mellitus and female sex in the risk of cholangiocarcinoma: A population-based nested case-control study.Oncotarget · 2017
   Article
4. Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives.ISRN hepatology · 2014
   Review
5. Unusual binding of ursodeoxycholic acid to ileal bile acid binding protein: role in activation of FXRα.Journal of lipid research · 2012
   Article
6. Impact of bile acids on the growth of human cholangiocarcinoma via FXR.Journal of hematology & oncology · 2011
   Article

Corrections and comments

• Comment on
  Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis.2003

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.